HLA-C and neoplasm: However, only certain tumor types and patients qualify for this therapeutic approach, in that checkpoint inhibition can only work in “hot” tumors that present sufficient numbers of MHC-restricted peptide antigens at their cell surface and that are infiltrated by tumor-reactive T-cells (1).